Off-Label Promotion: FDA Commissioner's Concerns Stem From Ethics Of Informed Consent
This article was originally published in The Pink Sheet Daily
'My personal view is that companies controlling that information is not the ideal,' Robert Califf tells BIO. 'That doesn’t mean I’ll carry the day.'
You may also be interested in...
Robert Califf offers some interesting clues as to how he’d handle top drug policy issues in his Senate confirmation hearing.
Discussions through the WHO are aimed at educating low- and middle-income countries, while efforts with ‘the larger regulators’ aim to reduce the development burden for products targeting ultra-rare diseases, CBER director Peter Marks tell DIA.
Acknowledging the toll that vaccine opponents have taken on FDA operations, the CBER director emphasizes the need to create stand-by manufacturing capacity, conduct faster studies in special populations, and better understand the mRNA platform.